Osteocytes and the pathogenesis of hypophosphatemic rickets
- PMID: 36246908
- PMCID: PMC9556901
- DOI: 10.3389/fendo.2022.1005189
Osteocytes and the pathogenesis of hypophosphatemic rickets
Abstract
Since phosphorus is a component of hydroxyapatite, its prolonged deprivation affects bone mineralization. Fibroblast growth factor 23 (FGF23) is essential for maintaining phosphate homeostasis and is mainly produced by osteocytes. FGF23 increases the excretion of inorganic phosphate (Pi) and decreases the production of 1,25-dihydroxyvitamin D in the kidneys. Osteocytes are cells of osteoblastic lineage that have undergone terminal differentiation and become embedded in mineralized bone matrix. Osteocytes express FGF23 and other multiple genes responsible for hereditary hypophosphatemic rickets, which include phosphate-regulating gene homologous to endopeptidase on X chromosome (PHEX), dentin matrix protein 1 (DMP1), and family with sequence similarity 20, member C (FAM20C). Since inactivating mutations in PHEX, DMP1, and FAM20C boost the production of FGF23, these molecules might be considered as local negative regulators of FGF23. Mouse studies have suggested that enhanced FGF receptor (FGFR) signaling is involved in the overproduction of FGF23 in PHEX-deficient X-linked hypophosphatemic rickets (XLH) and DMP1-deficient autosomal recessive hypophosphatemic rickets type 1. Since FGFR is involved in the transduction of signals evoked by extracellular Pi, Pi sensing in osteocytes may be abnormal in these diseases. Serum levels of sclerostin, an inhibitor Wnt/β-catenin signaling secreted by osteocytes, are increased in XLH patients, and mouse studies have suggested the potential of inhibiting sclerostin as a new therapeutic option for the disease. The elucidation of complex abnormalities in the osteocytes of FGF23-related hypophosphatemic diseases will provide a more detailed understanding of their pathogenesis and more effective treatments.
Keywords: fibroblast growth factor 23; mutation; osteocyte; phosphate; rickets.
Copyright © 2022 Yamazaki and Michigami.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.FASEB J. 2011 Aug;25(8):2551-62. doi: 10.1096/fj.10-177816. Epub 2011 Apr 20. FASEB J. 2011. PMID: 21507898 Free PMC article.
-
Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.J Bone Miner Res. 2013 Apr;28(4):899-911. doi: 10.1002/jbmr.1810. J Bone Miner Res. 2013. PMID: 23129509
-
Pathogenic role of Fgf23 in Dmp1-null mice.Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E254-61. doi: 10.1152/ajpendo.90201.2008. Epub 2008 Jun 17. Am J Physiol Endocrinol Metab. 2008. PMID: 18559986 Free PMC article.
-
Advances in understanding of phosphate homeostasis and related disorders.Endocr J. 2022 Aug 29;69(8):881-896. doi: 10.1507/endocrj.EJ22-0239. Epub 2022 Jul 13. Endocr J. 2022. PMID: 35831119 Review.
-
Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.Crit Rev Eukaryot Gene Expr. 2012;22(1):61-86. doi: 10.1615/critreveukargeneexpr.v22.i1.50. Crit Rev Eukaryot Gene Expr. 2012. PMID: 22339660 Free PMC article. Review.
Cited by
-
Microfluidic device for enhancement and analysis of osteoblast differentiation in three-dimensional cell cultures.J Biol Eng. 2023 Dec 14;17(1):77. doi: 10.1186/s13036-023-00395-z. J Biol Eng. 2023. PMID: 38098075 Free PMC article.
-
A deep intronic PHEX variant associated with X-linked hypophosphatemia in a Finnish family.JBMR Plus. 2024 Dec 23;9(2):ziae169. doi: 10.1093/jbmrpl/ziae169. eCollection 2025 Feb. JBMR Plus. 2024. PMID: 39877728 Free PMC article.
-
Role of the Osteocyte in Musculoskeletal Disease.Curr Osteoporos Rep. 2023 Jun;21(3):303-310. doi: 10.1007/s11914-023-00788-5. Epub 2023 Apr 21. Curr Osteoporos Rep. 2023. PMID: 37084017 Review.
-
Fibroblast Growth Factor 23 Bone Regulation and Downstream Hormonal Activity.Calcif Tissue Int. 2023 Jul;113(1):4-20. doi: 10.1007/s00223-023-01092-1. Epub 2023 Jun 12. Calcif Tissue Int. 2023. PMID: 37306735 Review.
-
Genome-Wide Differential Airway Gene Expression Analysis Identifies Genes Associated with COPD Comorbidities.Lung. 2025 Apr 26;203(1):58. doi: 10.1007/s00408-025-00814-6. Lung. 2025. PMID: 40287517 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous